This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Mr Alan Whitmore
Chief Scientific Officer at Tangram Therapeutics
Speaker

Profile

Alan Whitmore, BM, BCh, PhD, MRCGP, FFPM is the Chief Scientific Officer of Tangram Therapeutics, where he has been instrumental in the conception, design, implementation and development of the ETX computational drug discovery platform and its deployment into GalNAc-siRNA drug discovery and development. He is a clinician-scientist with over 30 years’ experience in cell and computational biology research, drug discovery and clinical medicine and has held a variety of roles including MRC Fellow, UCL Laboratory for Molecular Cell Biology; Visiting Fellow, The Jackson Laboratory, US; and Hon Senior Lecturer, UCL School of Pharmacy, as well as senior clinical management positions.

Agenda Sessions

  • TGM-312 - A Novel GalOmic GalNAc-siRNA for the Treatment of MASH

    14:30